Search - tctmd.com

Displaying 981 - 1000 of 1262

Sort: Relevancy | Date

News Daily News

Sixfold Higher Risk of Acute MI in the Week After Flu Diagnosis

Michael O'Riordan

January 24, 2018

News Daily News

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

Caitlin E. Cox

January 18, 2018

News Daily News

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

Caitlin E. Cox

January 08, 2018

News Daily News

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Michael O'Riordan

January 02, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Hospital Readmission Patterns Post-MI in China Differ Markedly From in the US

Yael L. Maxwell

December 07, 2017

News Daily News

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

Yael L. Maxwell

November 28, 2017

News Conference News AHA 2017

Pharmacist-Delivered Intervention Boosts Medication Adherence, but Not Risk Factor Control

Todd Neale

November 23, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

Long-Awaited Hypertension Guidelines Released at AHA

Todd Neale

November 13, 2017

Presentation TCT 2017

Beyond Heparin: When and How to Escalate Therapy for Acute PE (Lytics, Catheter-Based, Surgery)

Presenter: Peter P. Monteleone, Thomas M. Tu, Jay S. Giri

November 01, 2017

Presentation TCT 2017

Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials?

Presenter: James E. Udelson

November 01, 2017

Presentation TCT 2017

Is Functional Capacity a Suitable Endpoint for Heart Failure Drug and Device Trials?

Presenter: Angeles Alonso Garcia

November 01, 2017

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Industry News

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

October 02, 2017

News Daily News

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

L.A. McKeown

September 25, 2017

News Daily News

New Guidelines for Cardiogenic Shock Push for Regionalized Care, More Research

Shelley Wood

September 21, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

Advertisement

Sixfold Higher Risk of Acute MI in the Week After Flu Diagnosis

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

Heart Failure Risk Following 'Silent' MI Warrants Scrutiny: ARIC Analysis

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

TCTMD’s Top 10 Most Popular Stories for December 2017

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Hospital Readmission Patterns Post-MI in China Differ Markedly From in the US

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

Pharmacist-Delivered Intervention Boosts Medication Adherence, but Not Risk Factor Control

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Long-Awaited Hypertension Guidelines Released at AHA

Beyond Heparin: When and How to Escalate Therapy for Acute PE (Lytics, Catheter-Based, Surgery)

Are LV Volumes and Remodeling Suitable Endpoints for Heart Failure Drug and Device Trials?

Is Functional Capacity a Suitable Endpoint for Heart Failure Drug and Device Trials?

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

New Guidelines for Cardiogenic Shock Push for Regionalized Care, More Research

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content